Wednesday, June 08, 2016 1:23:17 PM
False! I did not say:
"DECN is no more than a nuisance to JNJ"
as you claim I said.
I wrote:
Please research and understand what a "nuisance suit" is.
DECN share price has a bearing in this case, as JNJ held down DECN's ability to market its product, so I would think the low SP will actually add to the value of the eventual settlement in Nevada.
As far as JNJ's SP, I am quite sure that it will not be affected by the losses to DECN. JNJ is coughing up settlements all the time
and their SP is yes, rising steadily even in the wake of these settlements which are far in excess (billions)of the millions they will have to pay DECN.
This is good, as it allows more funds to come DECN's way when JNJ has to pay for licensing to DECN.
"DECN is no more than a nuisance to JNJ"
as you claim I said.
I wrote:
You are stating this action by DECN is a nuisance suit
filed just to excite a few investors?
Please research and understand what a "nuisance suit" is.
DECN share price has a bearing in this case, as JNJ held down DECN's ability to market its product, so I would think the low SP will actually add to the value of the eventual settlement in Nevada.
As far as JNJ's SP, I am quite sure that it will not be affected by the losses to DECN. JNJ is coughing up settlements all the time
and their SP is yes, rising steadily even in the wake of these settlements which are far in excess (billions)of the millions they will have to pay DECN.
This is good, as it allows more funds to come DECN's way when JNJ has to pay for licensing to DECN.
Recent JNJ News
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/13/2026 03:15:34 PM
- Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision • Business Wire • 04/10/2026 12:00:00 PM
- Robotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value • InvestorsHub NewsWire • 04/09/2026 01:00:00 PM
- Robotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value • GlobeNewswire Inc. • 04/09/2026 12:30:00 PM
- Johnson & Johnson introduces VARIPULSE Pro in Europe after CE Mark clearance • IH Market News • 04/07/2026 02:12:35 PM
- Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe • Business Wire • 04/07/2026 12:00:00 PM
- Royalty Pharma signs $500M co-development agreement with J&J • IH Market News • 03/30/2026 12:28:19 PM
- J&J reports one-year ICOTYDE psoriasis trial results show sustained efficacy • IH Market News • 03/30/2026 09:32:48 AM
- ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis • PR Newswire (US) • 03/28/2026 02:00:00 PM
- Nanobiotix Shares Surge After Report of Possible Johnson & Johnson Takeover Interest • IH Market News • 03/25/2026 02:00:48 PM
- FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide • PR Newswire (US) • 03/18/2026 11:49:00 AM
- Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer • PR Newswire (US) • 03/13/2026 04:35:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 01:31:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 12:39:41 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 12:37:30 AM
- Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients • Business Wire • 03/12/2026 12:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/11/2026 10:17:23 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/11/2026 10:13:23 AM
- Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line • PR Newswire (US) • 03/05/2026 08:55:00 PM
- /C O R R E C T I O N -- Johnson & Johnson/ • PR Newswire (US) • 03/04/2026 12:36:00 AM
- Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE) • PR Newswire (US) • 03/03/2026 01:03:00 PM
- Johnson & Johnson to Host Investor Conference Call on First-Quarter Results • Business Wire • 03/02/2026 09:30:00 PM

